Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Update

Mustang Bio, Inc. (NASDAQ:MBIO) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 60,867 shares, a decline of 40.6% from the June 30th total of 102,440 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average trading volume of 41,980 shares, the short-interest ratio is currently 1.4 days.

Mustang Bio Stock Performance

Shares of MBIO stock traded down $0.03 during trading hours on Friday, reaching $0.56. The company had a trading volume of 8,905 shares, compared to its average volume of 135,144. The stock has a fifty day moving average of $0.67 and a 200-day moving average of $0.79. The company has a market capitalization of $4.24 million, a price-to-earnings ratio of -1.17 and a beta of 2.05. Mustang Bio has a 12-month low of $0.53 and a 12-month high of $1.88.

Mustang Bio (NASDAQ:MBIO) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($140.00) by $139.86.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mustang Bio in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Mustang Bio stock. DRW Securities LLC acquired a new stake in Mustang Bio, Inc. (NASDAQ:MBIO) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 73,936 shares of the company’s stock, valued at approximately $73,000. DRW Securities LLC owned 1.01% of Mustang Bio at the end of the most recent quarter. Hedge funds and other institutional investors own 9.95% of the company’s stock.

Mustang Bio Company Profile

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.